PG电子·(中国)官方网站

Share new trends in technology and health
Share new trends in technology and health

After ten years of sharpening a sword, Dongweien, a class 1 anti-hepatitis C drug, was approved for marketing!

知乎 头条

2020-12-22


On December 22, 2020, the State Food and Drug Administration issued an announcement that through the priority review and approval process, it approved the listing of the Class 1 anti-hepatitis C innovative drug Emitasvir Phosphate Capsule (trade name: Dongweien) declared by HEC!

Dongweien is an innovative drug independently developed by HEC with independent intellectual property rights. It is a non-structural protein (NS) 5A inhibitor for the treatment of adult genotype 1 non-cirrhotic chronic hepatitis C. According to the data, there are still at least 10 million chronic hepatitis C patients in my country. In 2019, the WHO set the goal of eliminating hepatitis C globally by 2030. The listing of Dongweien will contribute positively to the elimination of hepatitis C in my country.

Dongweien has undergone 10 years of research and development, including clinical approval and listing approval, which takes nearly 4 years of review. The R&D team of HEC started from scratch, and the down-to-earth, conscientious and responsible work finally achieved fruitful results, and achieved the first innovative drug of HEC on the market. HEC currently has a rich product pipeline, with 20 Class 1 drugs in clinical development, focusing on three indications of anti-infection, anti-tumor and endocrine metabolism. In the future, new drug products in the pipeline will also be gradually approved for marketing.

Related news

HEC has successfully challenged the first generic drug patent, and Fingolimod capsules have been approved for sale in the United States

2022-10-22

HEC has successfully challenged the first generic drug patent, and Fingolimod capsules have been approved for sale in the United States
友情链接: